It's clear after decades of research into this that nothing is "normal" when it comes to ME research. This could be a serious limitation of the PCR testing. We obviously don't know what is happening with the viruses inside our bodies. It could be they are so changed they no longer are comparable to "known" sequences.
IF this finding stands up to replication then it shows that we probably have a stronger anti-viral response than normal, and this to be expected from other findings, especially the RNaseL findings.
The quote about PCR is about standard PCR, not the cutting edge PCR variations that have been done. They have explicitly looked for unknown viruses. They have not found any. This is still ongoing however, they have not given up. Also the viral sequences that have been checked for include all known viruses, not just human viruses. However this latest test was on a short list of viruses for which it looks like they did some kind of quantitative PCR assay, assessing viral load. This is also different from an antibody assay.
Even an ICC or CCC ME diagnosis is probably heterogenous. It might not be, but it looks like it is to me, based on how findings split in studies with often a one third to two thirds split.
I would say there is considerable evidence of immunological abnormalities in individual cases. The problem is that there is no consistent abnormality even using ME diagnoses, though newer findings need more testing and replication and might well show such a finding ... or not.
For example, if ME is primarily metabolic then the immune system will also be impacted. There would be considerable variation I suspect, so the immune problems would vary. Also comorbidities and varying triggers might induce different immune markers.
The issue here is not that anyone considers there is no brain damage or immune damage, the issue is about quality of evidence. This is a massively under-funded area, all of ME research is. Large scale studies are very rare. Psychobabble studies are much larger than our biomedical studies. There is little funding to do otherwise. Similarly findings are not always even tested to see if they are replicable.
It is also important to consider the etiology of problems. The brain is highly sensitive to metabolic disturbance. However if Stanford can replicate their brain structural changes findings then there will be validated observable structural changes, showing something is substantially wrong in the brain. I hope to see those results next year.
I do support the use of modern ME definitions for research, and am not pro-SEID, but I am not sure its too far from an ME diagnosis. Its certainly better than Fukuda. Its deliberately simplified so it has a higher chance of catching a diagnosis, whereas for example the ICC is deliberately written to exclude any ME diagnosis that
might not be ME, to improve research cohort homogeneity. It will fail to diagnose many ME patients, as intended by design. However some of this can be improved by relaxing exclusion criteria in a clinical setting.
Let me give an example. OI and sleep apnoea are conditions in their own right. Yet both are common in ME. Its proper to exclude sleep apnoea patients in a research cohort, its improper to necessarily exclude them (unless the apnoea explains all symptoms) in a clinical definition. This is particularly the case since apnoea does not seem to induce PEM. Also its important to realise that Orthostatic Intolerance might itself be heterogeneous, and even in ME it possibly represents different comorbid disorders. This is before considering POTS versus NMH as well.
It is critical to exclude as many possible confounding disorders as possible in a research cohort. Its not always a good idea to do that in a clinical diagnosis. I am excluded from being in a research cohort due to potential immunological confounds from diabetes. Yet my diabetes is highly atypical, and I am not sure its not just ME induced glucose intolerance.
Not having a PEM diagnostic tool is a major concern. Its so very easy to misinterpret PEM, even in an ME diagnosis. This probably results in many non-ME patients being wrongly included in research cohorts. Now the newer work on energy metabolism, and refinements of CPET, may change that, but that is work in progress. If we had a PEM diagnostic test that is easy, cheap and reliable then I think many bad research cohorts would be caught out, such as ME diagnoses that are really depression. Even if we do not have an ME diagnostic test, we still need a PEM diagnostic test.
To reiterate, there are many patients who have ongoing viral infections, demonstrated brain problems, or demonstrated immunological problems. The issue is whether these are consistent enough to be considered either a common finding or even diagnostic.
The putative molecule that Ron is looking for that disables blood cell metabolic function might even be an antibody, or some other immune factor, though its far from certain. Again that is research we are waiting on.